MK 0677

Known as: MK 677, MK-0677, MK-677 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2018
0519952018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
BACKGROUND Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty… (More)
Is this relevant?
2005
2005
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… (More)
Is this relevant?
2004
2004
OBJECTIVES To evaluate the effects of MK-0677, an orally active growth hormone (GH) secretagogue, on functional recovery from hip… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Ghrelin is an acyl-peptide gastric hormone acting on the pituitary and hypothalamus to stimulate growth hormone (GH) release… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
GH increases bone turnover and stimulates osteoblast activity. We hypothesized that administration of MK-677, an orally active GH… (More)
Is this relevant?
1998
1998
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1998
1998
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… (More)
Is this relevant?
1997
1997
We have reported that MK-0677 is a novel, orally active GH secretagogue that stimulates an immediate and long-lasting increase in… (More)
Is this relevant?
1997
1997
Previous studies have indicated the existence of common mechanisms regulating sleep and somatotropic activity. In the present… (More)
Is this relevant?
1995
1995
A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been… (More)
Is this relevant?